A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty around Eylea's U.S. market exclusivity. At the time, Leerink's Risinger ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Regeneron stock jumped Thursday ... High-dose Eylea came in at $200 million, beating expectations for $189 million, Leerink Partners analyst David Risinger said in a report.

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With this FDA decision, Dupixent is now approved for seven ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

Leerink analyst Andrew Berens notes that Outperform-rated Incyte (INCY) has reported the results of the two parallel Phase 3 trials evaluating povorcitinib in hidradenitis suppurativa, STOP-HS1 ...